Saroglitazar: FIRST GLITAZAR TO GAIN REGULATORY NOD

SAROGLITAZAR : FIRST GLITAZAR TO GAIN REGULATORY NOD Saroglitazar is a novel glitazar compound developed indigenously in India and gained regulatory approval from the Indian regulatory authority DCGI in June 2013.18 It was developed by Zydus Cadilla and is available under the trade name LipaglynTM. Saroglitazar is a dual PPAR agonist that lowers cholesterol and improves glucose control in type 2 diabetes. Learn how to use it, what side effects to expect, and what precautions to take with other medicines. Learn about Saroglitazar , a medication used for managing dyslipidemia in patients with type 2 diabetes. Explore its indications, dosage, contraindications, precautions, and potential side effects. Stay informed about drug interactions for safe and effective use. Bilypsa is used for Noncirrhotic Non-Alcoholic Steatohepatitis, Type 2 diabetes mellitus, Non-alcoholic fatty liver disease. Know it’s uses, side effects, reviews, composition and precautions only on 1mg.